Professor Oliver Maddocks is a cancer biologist whose work examines how tumours respond to metabolic stress and exploit nutrient availability to support survival and treatment resistance. His research identifies metabolic vulnerabilities—particularly in responses to amino‑acid deprivation and oxidative stress—that can be leveraged to make cancer cells more sensitive to therapy.
Professor Maddocks holds an MPharm from Cardiff University, a PhD from the University of Edinburgh, was a Fulbright Scholar at the University of Maryland School of Medicine, and is currently Chief Scientific Officer and Co‑Founder of Faeth as well as an Honorary Professor at the University of Glasgow.
In this talk, he will first present an optimised multi‑node inhibition strategy targeting the PI3K/AKT/mTOR pathway, combining drug and dietary interventions now in Phase 2 clinical development. He will then explore how cancer cells rely on specific exogenous amino acids, and how these metabolic dependencies may be therapeutically exploited in clinical settings.